Neuro oncology News and Research

RSS

Clinical trial demonstrates safety of targeted treatment approach for deadly brain tumor in children

A Phase I clinical trial demonstrated that a targeted approach to treating a deadly brain tumor in children called diffuse intrinsic pontine glioma (DIPG) is safe, reported Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center investigators.

3 Apr 2025

New targeted therapy shows early success in treating pediatric high-grade gliomas

An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma.

20 Mar 2025

New technique effectively identifies aggressive medulloblastoma

Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma-the most common type of malignant brain tumour in children-and potentially sparing young patients from unnecessary treatments and their harmful long-term side effects.

12 Mar 2025

Breakthrough drug more than doubles survival in glioblastoma patients

A drug developed at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been shown to extend survival for patients with glioblastoma, the most common primary brain tumor in adults.

7 Mar 2025

Neuroscientists win The Brain Prize 2025 for pioneering research into brain cancer

Gliomas are types of cancers that arise in the brain and are extraordinarily difficult to treat. They are the leading cause of brain tumour-related deaths in both children and adults.

5 Mar 2025

Human-specific gene variant may hold key to evolution of language

The origins of human language remain mysterious. Are we the only animals truly capable of complex speech? Are Homo sapiens the only hominids who could give detailed directions to a far-off freshwater source or describe the nuanced purples and reds of a dramatic sunset?

18 Feb 2025

UCLA Health receives $1.72 million grant to advance brain tumor research and training

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have been awarded a $1.72 million grant from the National Institutes of Health to support the Neuro-Oncology Translational Research Training Program, an initiative designed to train the next generation of brain tumor scientists and physician-scientists.

4 Feb 2025

USC receives $6 million grant for pioneering glioblastoma gene therapy

The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new first-of-its-kind genetic therapy for glioblastoma, a severe form of brain cancer.

3 Feb 2025

Asymptomatic brain metastasis in stage 4 breast cancer requires reevaluation of screening guidelines

A new study led by researchers at Moffitt Cancer Center shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed.

28 Jan 2025

New AI model offers hope for detecting brain cancer spread without surgery

Researchers have developed an artificial intelligence (AI) model to detect the spread of metastatic brain cancer using MRI scans, offering insights into patients' cancer without aggressive surgery.

15 Jan 2025

Temozolomide and radiation combination improves survival in low-grade glioma patients

Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas.

25 Nov 2024

New study unveils why glioblastoma becomes resistant to treatment

A new study from scientists at the UCLA Health Jonsson Comprehensive Cancer Center helps explain why glioblastoma, one of the most aggressive forms of brain cancer, becomes resistant to treatment, and introduces a new approach that paves the way for more personalized treatment strategies for patients with this deadly brain tumor.

22 Nov 2024

International team releases recommendations for AI use in neuro-oncology

An international, multidisciplinary team of leading neuro-oncology researchers and clinicians has released new recommendations for good clinical practice - a set of guidelines that helps ensure clinical trial results are reliable, and patients are protected - regarding the use of artificial intelligence methods to more accurately diagnose, monitor and treat brain cancer patients.

15 Nov 2024

Major studies reveal improved treatment for children with Group 3 medulloblastoma

Vital research findings pointing to improved treatment for children with Group 3 medulloblastoma brain tumors have been revealed in two major studies published in the journal Neuro-Oncology.

9 Oct 2024

Innovative CAR-T cells effectively target glioblastoma with reduced toxicity

Glioblastoma is the most common and most aggressive primary brain tumor, with an average survival after diagnosis of less than two years, and against which current treatments remain ineffective.

26 Sep 2024

Hybrid neuron-glia cells found in glioma may impact tumor growth

Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital have uncovered a new cell type in the human brain.

5 Sep 2024

CDK4/6 inhibitors show promise for pediatric high-grade glioma treatment

CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to new research from Dana-Farber Cancer Institute and the Institute of Cancer Research in London.

3 Sep 2024

Drug shows new promise in treating breast cancer with brain metastases or recurrent glioblastoma

A drug effective in treating breast cancer shows new promise in addressing breast cancer with brain metastases or recurrent glioblastoma, as reported by results of a prospective window-of-opportunity trial at the University of Texas Health Science Center at San Antonio (UT Health San Antonio).

8 Aug 2024

Decoding glioblastoma: New insights into molecular subtypes and mesenchymal transition mechanisms

Glioblastoma multiforme (GBM) stands as a formidable adversary in oncology, characterized by its molecular complexity and relentless progression.

7 Aug 2024

FDA approves vorasidenib for Grade 2 gliomas with IDH mutations

Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations.

6 Aug 2024